Abstract
The medical treatment of acute pancreatitis continues to focus on supportive care, including fluid therapy, nutrition, and antibiotics, all of which will be critically reviewed. Pharmacologic agents that were previously studied were found to be ineffective likely due to a combination of their targets and flaws in trial design. Potential future pharmacologic agents, particularly those that target intracellular calcium signaling, as well as considerations for trial design will be discussed. As the incidence of acute pancreatitis continues to increase, greater efforts will be needed to prevent hospitalization, readmission and excessive imaging in order to reduce overall healthcare costs. Primary prevention continues to focus on post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis and secondary prevention on cholecystectomy for biliary pancreatitis as well as alcohol and smoking abstinence.
Original language | English (US) |
---|---|
Pages (from-to) | 901-911 |
Number of pages | 11 |
Journal | Expert Review of Gastroenterology and Hepatology |
Volume | 9 |
Issue number | 7 |
DOIs | |
State | Published - Sep 1 2015 |
Keywords
- acute pancreatitis
- clinical trials
- drugs
- medical therapy
- primary prevention
- resource utilization
- secondary prevention
ASJC Scopus subject areas
- Hepatology
- Gastroenterology